Company profile
AC Immune SA
NASDAQ:ACIUBiotechnology: Pharmaceutical Preparations
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07463196 | phase1 | recruiting | 2026-01-28 | 2026-12-01 | AC Immune SA | A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors |
| NCT04373616 | phase2 | withdrawn | 2021-10-01 | 2024-04-01 | AC Immune SA | A Study of ACI-24 in Adults With Down Syndrome |
| NCT05462106 | phase1_2 | recruiting | 2022-06-21 | 2029-04-01 | AC Immune SA | A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) |
| NCT06015841 | phase2 | active_not_recruiting | 2023-07-24 | 2028-01-01 | AC Immune SA | A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease |
| NCT04445831 | phase1_2 | completed | 2019-07-31 | 2023-09-05 | AC Immune SA | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease |
FDA applications (0)
No records yet.